Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06055361 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
A Phase 1 study of Atopic Dermatitis, sponsored by Brexogen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 3
- Study locations
NCT06055361: Recruiting Phase 1 study of Atopic Dermatitis, sponsored by Brexogen.
NCT06055361 is a Phase 1 study of Atopic Dermatitis that is actively recruiting participants, run by Brexogen. The registered enrollment target is 45 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06055361, a Phase 1 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Brexogen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
Primary Outcome
Incidence of treatment-emergent adverse events as assessed by CTCAE v5.0
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BxC-I17e (primed iMSC derived Extracellular vesicles(EV))
Study Locations (3)
Pennsylvania
- DermDox Centers for Dermatology - Camp Hill
- University of Pennsylvania - Philadelphia
Arkansas
- Arkansas Research Trials - North Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
What NCT06055361 shows while recruiting
NCT06055361 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06055361 reports a single indexed study location in Pennsylvania, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06055361 about?
NCT06055361 is a clinical study titled "A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis". The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
What is the current status of trial NCT06055361?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2023-04-18. Estimated completion is 2026-03-31.
What conditions does trial NCT06055361 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06055361?
The interventions under investigation include: Placebo (DRUG), BxC-I17e (primed iMSC derived Extracellular vesicles(EV)) (DRUG).
Who is sponsoring clinical trial NCT06055361?
This trial is sponsored by Brexogen, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06055361 being conducted?
This trial has 3 study locations across Arkansas, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06055361's enrollment target sits among peer trials
45 111th of 150 higher than 39 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
-
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI